Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Pedro Machado and Jinoos Yazdany.
Connection Strength

2.739
  1. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers. Ann Rheum Dis. 2021 Feb 18.
    View in: PubMed
    Score: 0.930
  2. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 23.
    View in: PubMed
    Score: 0.241
  3. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 13.
    View in: PubMed
    Score: 0.240
  4. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al. Ann Rheum Dis. 2021 May 13.
    View in: PubMed
    Score: 0.236
  5. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al. Ann Rheum Dis. 2021 Mar 01.
    View in: PubMed
    Score: 0.233
  6. Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. Curr Opin Rheumatol. 2021 03 01; 33(2):111-116.
    View in: PubMed
    Score: 0.233
  7. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021 Oct; 3(10):e707-e714.
    View in: PubMed
    Score: 0.060
  8. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
    View in: PubMed
    Score: 0.059
  9. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
    View in: PubMed
    Score: 0.058
  10. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
    View in: PubMed
    Score: 0.058
  11. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology (Oxford). 2021 01 05; 60(1):353-358.
    View in: PubMed
    Score: 0.058
  12. Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al. Ann Rheum Dis. 2020 Sep 07.
    View in: PubMed
    Score: 0.056
  13. COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al. Ann Rheum Dis. 2020 Aug 12.
    View in: PubMed
    Score: 0.056
  14. Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi et al. Ann Rheum Dis. 2020 Jun 30.
    View in: PubMed
    Score: 0.056
  15. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
    View in: PubMed
    Score: 0.055
  16. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020 10; 79(10):1386-1388.
    View in: PubMed
    Score: 0.055
  17. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 May; 2(5):e250-e253.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.